Shuttle Pharmaceuticals Reports Material Agreement Changes
Ticker: SHPH · Form: 8-K · Filed: Oct 21, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $10,000,000, $1.091 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
Shuttle Pharma entered and exited a big deal on Oct 15th. Details TBD.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on October 21, 2025, reporting events that occurred on October 15, 2025. The filing indicates both the entry into and termination of a material definitive agreement, along with financial statements and exhibits. Specific details regarding the nature of these agreements and their financial implications are not provided in this excerpt.
Why It Matters
This filing signals significant corporate actions, potentially impacting the company's operations, partnerships, or financial standing, requiring further investigation into the specifics of the agreements.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions (entry and termination of material agreements) without immediate detail, creating uncertainty.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- October 15, 2025 (date) — Earliest event reported
- October 21, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, MD (location) — Principal executive offices
FAQ
What was the material definitive agreement that Shuttle Pharmaceuticals Holdings, Inc. entered into on October 15, 2025?
The filing does not specify the details of the material definitive agreement entered into on October 15, 2025.
What was the reason for the termination of the material definitive agreement on October 15, 2025?
The filing does not provide the reason for the termination of the material definitive agreement.
Are the financial statements and exhibits related to the entry or termination of the material definitive agreement?
The filing states that financial statements and exhibits are included, but does not explicitly link them to the specific agreement events.
What is the business address of Shuttle Pharmaceuticals Holdings, Inc.?
The business address is 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is the telephone number for Shuttle Pharmaceuticals Holdings, Inc.?
The telephone number is (240) 430-4212.
Filing Stats: 789 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2025-10-21 16:05:44
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $10,000,000 — and liabilities for a purchase price of $10,000,000 payable in a combination of cash and sh
- $1.091 million — d thereunder in the aggregate amount of $1.091 million. Theradex is the Company's primary thir
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 34KB
- 0001493152-25-018788.txt ( ) — 247KB
- shph-20251015.xsd (EX-101.SCH) — 3KB
- shph-20251015_lab.xml (EX-101.LAB) — 33KB
- shph-20251015_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: October 21, 2025 By: /s/ Christopher Cooper Name: Christopher Cooper Title: Interim Chief Executive Officer